Besides, serum IL-6 and IL-8 levels were higher in patients with TP53 mutation compared to TP53 wild-type tumours, while serum IL-6 and IL-10 levels were higher in patients with EML4-ALK variant 3 (V3) compared to V1/V2-driven tumours (Supplementary Fig. 6), indicating an association between serum cytokines levels and molecular risk factors of ALK + tumours. This evidence concerns the gene EML4 and neoplasm.